Chemed (NYSE:CHE) Given Hold (C-) Rating at Weiss Ratings

Key Points

• Chemed's stock has been given a hold (C-) rating by Weiss Ratings, indicating a neutral outlook on the company's current performance.
• Analysts have shown mixed sentiments with four rating the stock as a buy while one assigned a hold rating, reflecting a Moderate Buy average rating overall.
• Chemed reported earnings per share (EPS) of $4.27 for the last quarter, falling short of expectations and showing a decrease compared to the previous year's EPS of $5.47.

Chemed (NYSE:CHE - Get Free Report)'s stock had its "hold (c-)" rating restated by stock analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

CHE has been the subject of a number of other research reports. Wall Street Zen lowered shares of Chemed from a "buy" rating to a "hold" rating in a research note on Saturday, July 5th. Bank of America dropped their target price on shares of Chemed from $610.00 to $595.00 and set a "buy" rating for the company in a research note on Wednesday, September 10th. Jefferies Financial Group raised shares of Chemed from a "hold" rating to a "buy" rating and upped their target price for the company from $490.00 to $550.00 in a research note on Tuesday, September 2nd. Royal Bank Of Canada reduced their target price on shares of Chemed from $640.00 to $589.00 and set an "outperform" rating for the company in a report on Thursday, July 31st. Finally, Oppenheimer dropped their price target on shares of Chemed from $650.00 to $580.00 and set an "outperform" rating on the stock in a research report on Thursday, July 31st. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $578.50.

Chemed Price Performance

CHE traded down $1.28 during trading on Wednesday, hitting $434.80. The company's stock had a trading volume of 169,417 shares, compared to its average volume of 208,497. Chemed has a twelve month low of $408.42 and a twelve month high of $623.60. The stock has a market cap of $6.34 billion, a PE ratio of 22.35, a PEG ratio of 2.54 and a beta of 0.43. The firm's 50 day moving average price is $447.87 and its 200-day moving average price is $513.00.

Chemed (NYSE:CHE - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $4.27 earnings per share for the quarter, missing the consensus estimate of $6.02 by ($1.75). Chemed had a return on equity of 25.83% and a net margin of 11.56%.The business had revenue of $618.80 million for the quarter, compared to analyst estimates of $650.60 million. During the same quarter last year, the company earned $5.47 EPS. Chemed's revenue was up 3.8% compared to the same quarter last year. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. Equities analysts anticipate that Chemed will post 21.43 earnings per share for the current year.

Insider Transactions at Chemed

In other Chemed news, Director Patrick P. Grace sold 150 shares of the company's stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $463.39, for a total value of $69,508.50. Following the completion of the sale, the director directly owned 3,397 shares in the company, valued at approximately $1,574,135.83. This represents a 4.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin J. Mcnamara sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $461.28, for a total value of $1,383,840.00. Following the completion of the transaction, the chief executive officer owned 96,197 shares in the company, valued at approximately $44,373,752.16. This trade represents a 3.02% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,162 shares of company stock worth $5,677,511. 3.29% of the stock is owned by insiders.

Hedge Funds Weigh In On Chemed

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bessemer Group Inc. grew its position in Chemed by 14.2% during the 1st quarter. Bessemer Group Inc. now owns 950 shares of the company's stock worth $585,000 after purchasing an additional 118 shares in the last quarter. DAVENPORT & Co LLC acquired a new stake in shares of Chemed during the first quarter worth $265,000. Jump Financial LLC bought a new position in shares of Chemed in the 1st quarter valued at about $2,777,000. Mather Group LLC. boosted its holdings in Chemed by 53.3% in the 1st quarter. Mather Group LLC. now owns 161 shares of the company's stock valued at $99,000 after purchasing an additional 56 shares during the period. Finally, Park Place Capital Corp increased its position in Chemed by 71.2% in the 1st quarter. Park Place Capital Corp now owns 3,572 shares of the company's stock valued at $2,198,000 after acquiring an additional 1,486 shares during the period. 95.85% of the stock is currently owned by institutional investors and hedge funds.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.